Description

AbbVie’s Bold Obesity Play Could Up Its Game In The GLP-1 Domain—Here’s What You Need to Know!

AbbVie Inc. recently reported its results for the first quarter of 2025, showcasing strong performance across various therapeutic areas. The company’s adjusted earnings per share were $2.46, surpassing the guidance midpoint by $0.10. Total net revenues stood at over $13.3 billion, a remarkable increase of roughly $550 million beyond expectations. These figures demonstrate the robust sales growth of AbbVie’s ex-Humira platform, which showcased a strong sales growth of over 21%.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!